The price of whey protein has risen fivefold as the soaring popularity of GLP-1 weight-loss drugs reshapes global demand for the dairy ingredient, pushing costs to record levels and squeezing manufacturers who cannot keep up.
Data from DCA Market Intelligence shows that food-grade whey powder across north-west Europe has reached approximately €1,700 (£1,469) per tonne, the highest level on record, with prices up more than 50% since the start of 2026. Commodity intelligence platform Vesper puts the price of whey protein concentrate with 80% protein — the most widely used form — at £23,751 per tonne in June this year, compared with £4,302 in June 2023. In the United States, inventories of whey protein have fallen by half since 2023, and prices have surged by more than 50% since January, with whey protein isolate reaching an unprecedented $11 per pound ($24,250 per metric tonne).
Why GLP-1 drugs are driving the protein boom
The surge is being fuelled by the widespread adoption of GLP-1 receptor agonists — drugs such as semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) — which are used for weight loss and diabetes management. These medications work by suppressing appetite and slowing gastric emptying, leading patients to eat significantly less. However, rapid weight loss carries the risk of losing lean muscle mass alongside fat, and health professionals consistently advise GLP-1 users to increase their protein intake to help preserve muscle.
While some research suggests that GLP-1 drugs primarily reduce fat mass by 80-85% and largely preserve skeletal muscle in relative terms, the concern over lean mass loss remains a central factor driving dietary advice. This has even spurred research into experimental drugs designed to retain muscle during GLP-1 treatment. The broader effect is clear: patients on these medications tend to shift their dietary preferences towards protein, fibre and minimally processed foods, and they display a higher willingness-to-pay for protein-rich products, showing less sensitivity to price increases than other consumers.
Whey protein — a by-product of cheese-making that contains all nine essential amino acids and is easily absorbed by the body — has become the supplement of choice for this purpose. Its demand is no longer limited to bodybuilders and athletes. Food manufacturers are reformulating products to cater to what is being called the “GLP-1 premium”, adding whey protein to an expanding range of everyday items. “Once GLP-1s started soaring, people realised how important protein is in their diet,” said Erika Tamayo, founder of the UK-based protein brand Hermosa. “Then loads of products in mainstream supermarkets started adding whey protein to everything — popcorn, crisps, even protein doughnuts. Everything now has protein in it because of the focus on diets.”
Supply cannot keep up with demand
The problem is that whey protein supply is intrinsically linked to cheese output, making it impossible to scale up rapidly. This inelasticity, combined with surging demand, has created a volatile market prone to sharp price movements. Jasper Endlich, an analyst at Vesper, said: “If you look at overall supply and demand, the market is still finding a home for the product, but there’s clearly a shortage in the sense that people want more than there physically is available. Manufacturers would like to produce more and build safety stocks, but they haven’t been able to do that.”
The United States Department of Agriculture’s Dairy Market News highlights a tightening market, particularly for whey protein concentrate (WPC) 34%, a commercial ingredient used widely in processed foods. Prices for WPC 34% are rising across the board, with the strongest increases at the top end of the market. Some suppliers are already sold out for the remainder of 2026, and one manufacturer is expected to stop producing WPC 34% after the summer, which market participants believe will further reduce availability. DCA Market Intelligence reports similar strain at the higher end: WPC80, the most concentrated form, is seeing strong demand and longer lead times, with the ingredient transitioning from a by-product to a product with active demand in its own right.
Small businesses feel the pressure
The cost increases are hitting smaller companies hardest. Hermosa, which sources its ingredients from UK farmers and sells grass-fed whey and vegan protein powders, has seen its costs double quarter-on-quarter. “On the last two years, we’ve noticed every quarter the price is soaring up,” Tamayo said. “We are managing to source protein, but we’re buying it at double the cost compared to last quarter. We still have stock from our last order and won’t immediately pass that on to our clients, but at some point I will have to.”
She described a market in which larger players are absorbing price increases in the scramble for market share, while smaller businesses struggle to compete. “We are now all fighting for stock allocation. Some of the bigger companies have absorbed all the price increases as they’re all trying to get market share and grow their businesses. Bigger players have more possibilities, so they don’t have to compromise. For a small business with a small range of products, it is harder. We don’t want to compromise on being a luxury and premium product.”
Tamayo added that managing lead times has become a constant challenge: “Every quarter we have to wait and see how much supply is available, while also buying months in advance to make sure we don’t run out of stock.”
How the market is responding
Despite the strain, industry experts say the market is already adapting. Endlich noted that new production plants are opening, and manufacturers are exploring alternative formulations. “Where products may once have contained only whey protein, some are now using blends with a small amount of milk protein mixed in. The overall protein content remains broadly similar, but the ingredient cost can be half or even a third of the price. There are ways for companies to manage the pressure while supply catches up.”
The UK whey protein market — valued at around £581.8 million in 2024 — is projected to grow to approximately £1.2 billion by 2033, a compound annual growth rate of 8.2%. Major players in the UK include Arla Foods amba, First Milk Limited, Glanbia PLC, Kerry Group plc and Royal FrieslandCampina N.V. The broader trend towards high-protein diets is also reflected in consumer behaviour beyond the GLP-1 cohort, with protein supplements surging in popularity not just among athletes but for everyday strength and recovery.
Broader supply chain risks
The current crunch comes against a backdrop of broader vulnerabilities in the UK food supply chain, which faces increasing risks from cyberattacks, extreme weather, fuel shortages and global trade disruptions, exacerbated by geopolitical conflicts and reliance on imports. These factors contribute to inflationary pressures on food ingredients. There is a growing emphasis in the UK on strengthening short food supply chains and increasing domestic food production to enhance resilience.
The GLP-1 market itself continues to expand rapidly. The sector is dominated by Novo Nordisk and Eli Lilly, but numerous other pharmaceutical companies — including Pfizer, Roche, Amgen and Viking Therapeutics — are developing new formulations, including oral and monthly injectable options. Market projections for GLP-1 drugs reach as high as $180 billion by 2034, suggesting that the dietary shifts they trigger will persist for years to come.
